Periodic paralyses (PPs) are rare neuromuscular disorders caused by mutations in skeletal muscle sodium, calcium, and potassium channel genes. PPs include hypokalemic paralysis, hyperkalemic paralysis, and Andersen-Tawil syndrome. Common features of PP include autosomal dominant inheritance, onset typically in the first or second decades, episodic attacks of flaccid weakness, which are often triggered by diet or rest after exercise. Diagnosis is based on the characteristic clinic presentation then confirmed by genetic testing. In the absence of an identified genetic mutation, documented low or high potassium levels during attacks or a decrement on long exercise testing support diagnosis. The treatment approach should include both management of acute attacks and prevention of attacks. Treatments include behavioral interventions directed at avoidance of triggers, modification of potassium levels, diuretics, and carbonic anhydrase inhibitors.

Review of the Diagnosis and Treatment of Periodic Paralysis / J.M. Statland, B. Fontaine, M.G. Hanna, N.E. Johnson, J.T. Kissel, V.A. Sansone, P.B. Shieh, R.N. Tawil, J. Trivedi, S.C. Cannon, R.C. Griggs. - In: MUSCLE & NERVE. - ISSN 1097-4598. - 57:4(2018 Apr), pp. 522-530.

Review of the Diagnosis and Treatment of Periodic Paralysis

V.A. Sansone;
2018

Abstract

Periodic paralyses (PPs) are rare neuromuscular disorders caused by mutations in skeletal muscle sodium, calcium, and potassium channel genes. PPs include hypokalemic paralysis, hyperkalemic paralysis, and Andersen-Tawil syndrome. Common features of PP include autosomal dominant inheritance, onset typically in the first or second decades, episodic attacks of flaccid weakness, which are often triggered by diet or rest after exercise. Diagnosis is based on the characteristic clinic presentation then confirmed by genetic testing. In the absence of an identified genetic mutation, documented low or high potassium levels during attacks or a decrement on long exercise testing support diagnosis. The treatment approach should include both management of acute attacks and prevention of attacks. Treatments include behavioral interventions directed at avoidance of triggers, modification of potassium levels, diuretics, and carbonic anhydrase inhibitors.
acetazolamide; Andersen-Tawil syndrome; channelopathies; dichlorphenamide; periodic paralyses; review; treatment
Settore MED/26 - Neurologia
apr-2018
nov-2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
Statland_et_al-2017-Muscle_&_Nerve.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 675.78 kB
Formato Adobe PDF
675.78 kB Adobe PDF Visualizza/Apri
Statland_et_al-2017-Muscle_&_Nerve.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 157.79 kB
Formato Adobe PDF
157.79 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/531758
Citazioni
  • ???jsp.display-item.citation.pmc??? 45
  • Scopus 126
  • ???jsp.display-item.citation.isi??? 110
social impact